Publication:
International prospective study Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial infections

dc.contributor.authorDURMUŞOĞLU, LÜTFİYE
dc.contributor.authorsPaterson, DL; Ko, WC; Von Gottberg, A; Mohapatra, S; Casellas, JM; Goossens, H; Mulazimoglu, L; Trenholme, G; Klugman, KP; Bonomo, RA; Rice, LB; Wagener, MM; McCormack, JG; Yu, VL
dc.date.accessioned2022-03-12T17:17:54Z
dc.date.accessioned2026-01-11T19:02:09Z
dc.date.available2022-03-12T17:17:54Z
dc.date.issued2004
dc.description.abstractBackground: Commonly encountered nosocomially acquired gram-negative bacteria, especially Klebsiella pneumoniae, produce extended-spectrum beta-lactamases (ESBLs) as an antibiotic resistance mechanism. Objective: To determine whether microbiology laboratories should report the presence of ESBLs and to establish the infection-control implications of ESBL-producing organisms. Design: Prospective observational study. Setting: 12 hospitals in South Africa, Taiwan, Australia, Argentina, the United States, Belgium, and Turkey. Patients: 440 patients with 455 consecutive episodes of K. pneumoniae bacteremia between 1 January 1996 and 31 December 1997; of these, 253 episodes were nosocomially acquired. Measurements: The K. pneumoniae isolates were examined for the presence of ESBLs. Pulsed-field gel electrophoresis was used to analyze the molecular epidemiology of nosocomial bacteremia with ESBL-producing K. pneumoniae. Results: Overall, 30.8% (78 of 253) episodes of nosocomial bacteremia and 43.5% (30 of 69) episodes acquired in intensive care units were due to ESBL-producing organisms. After adjustment for potentially confounding variables, previous administration of beta-lactam antibiotics containing an oxyimino group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was associated with bacteremia due to ESBL-producing strains (risk ratio, 3.9 [95% Cl, 1.1 to 13.8]). In 7 of 10 hospitals with more than 1 ESBL-producing isolate, multiple strains with the same genotypic pattern were observed, indicating patient-to-patient spread of the organism. Conclusions: Production of ESBLs; by Klebsiella pneumoniae is a widespread nosocomial problem. Appropriate infection control and antibiotic management strategies are needed to stem the spread of this emerging form of resistance.
dc.identifier.doi10.7326/0003-4819-140-1-200401060-00008
dc.identifier.eissn1539-3704
dc.identifier.issn0003-4819
dc.identifier.pubmed14706969
dc.identifier.urihttps://hdl.handle.net/11424/227907
dc.identifier.wosWOS:000187855600004
dc.language.isoeng
dc.publisherAMER COLL PHYSICIANS
dc.relation.ispartofANNALS OF INTERNAL MEDICINE
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCEFTAZIDIME RESISTANCE
dc.subjectANTIBIOTIC-RESISTANCE
dc.subjectOUTBREAK
dc.subjectTHERAPY
dc.subjectEPIDEMIOLOGY
dc.subjectMONOTHERAPY
dc.subjectINHIBITORS
dc.titleInternational prospective study Klebsiella pneumoniae bacteremia: Implications of extended-spectrum beta-lactamase production in nosocomial infections
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage32
oaire.citation.issue1
oaire.citation.startPage26
oaire.citation.titleANNALS OF INTERNAL MEDICINE
oaire.citation.volume140

Files